Novel salt forms of poorly soluble probucol esters and ethers
AssigneeAtheroGenics, Inc.
InventorCharles Q. Meng
Life of this patent
Estimating the term…
Abstract
Organic amine salts of compounds of the formula: 1 and their pharmaceutically acceptable salts, and uses in medical therapy are provided.
Claims94
A meglumine salt represented by the formula:
- 25
- wherein:
- R1 and R2 are independently hydrogen or alkyl or taken together to form a carbonyl;
- and
- Y is (CH2)0-5;
- and when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5.
A meglumine salt represented by the formula:
- 26
- wherein:
- Y is (CH2)1-5.
A meglumine salt represented by the formula:
- 27
- wherein:
- Y is (CH2)0-5.
A meglumine salt selected from the group consisting of:
- butanedioic acid, mono [4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]ester, meglumine salt;
- acetic acid, [4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methyl-ethyl] thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, meglumine salt;
- and butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)4-hydroxyphenyl]thio]-1-methyl-ethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, meglumine salt.
A pharmaceutical composition comprising a meglumine salt represented by the formula:
- 28
- wherein:
- R1 and R2 are independently hydrogen or alkyl or taken together to form a carbonyl;
- and
- Y is (CH2)0-5;
- when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
- together with a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a meglumine salt represented by the formula:
- 29
- wherein:
- Y is (CH2)1-5;
- together with a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a meglumine salt represented by the formula:
- 30
- wherein:
- Y is (CH2)0-5;
- when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
- together with a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a compound of the formula:
- 31
- wherein:
- R1 and R2 are independently hydrogen or alkyl or taken together to form a carbonyl;
- and
- Y is (CH2)0-5;
- when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
- together with meglumine and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a compound of the formula:
- 32
- wherein:
- Y is (CH2)1-5;
- together with meglumine and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a compound of the formula:
- 33
- wherein:
- Y is (CH2)0-5;
- when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
- together with meglumine and a pharmaceutically acceptable carrier.
An organic amine salt represented by the formula:
- 34
- wherein:
- R1 and R2 are independently hydrogen or alkyl or taken together to form a carbonyl;
- and
- Y is (CH2)0-5;
- when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5.
An organic amine salt represented by the formula:
- 35
- wherein:
- Y is (CH2)1-5.
An organic amine salt represented by the formula:
- 36
- wherein:
- Y is (CH2)0-5.
A pharmaceutical composition represented by the formula:
- 37
- wherein:
- R1 and R2 are independently hydrogen or alkyl or taken together to form a carbonyl;
- and
- Y is (CH2)0-5;
- when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
- together with a pharmaceutically acceptable carrier.
A pharmaceutical composition represented by the formula:
- 38
- wherein:
- Y is (CH2)1-5;
- together with a pharmaceutically acceptable carrier.
A pharmaceutical composition represented by the formula:
- 39
- wherein:
- Y is (CH2)0-5;
- when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
- together with a pharmaceutically acceptable carrier.
A compound of the formula:
- 40
- wherein:
- R1 and R2 are independently hydrogen or alkyl or taken together to form a carbonyl;
- and
- Y is (CH2)0-5;
- when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
- together with an organic amine, optionally in a pharmaceutically acceptable carrier.
A compound of the formula:
- 41
- wherein:
- Y is (CH2)1-5;
- together with an organic amine, optionally in a pharmaceutically acceptable carrier.
A compound of the formula:
- 42
- wherein:
- Y is (CH2)0-5;
- together with an organic amine, optionally in a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.